Last reviewed · How we verify

NCT06658821

The Effect of LDL557 on Improving Degenerative Arthritis in the Elderly

ENROLLING BY INVITATION NA Last updated 30 September 2025
What this trial tests

NA trial testing LDL557-HK capsule in Arthritis in 100 participants. Enrolling by invitation.

Timeline
27 February 2025
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorChung Shan Medical University
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposehealth services research
Enrollment100
Start date27 February 2025
Primary completion30 June 2026
Estimated completion30 June 2026
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Chung Shan Medical University

Who can join

Adults 45 to 80, any sex, with Arthritis or Joint Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project is to conduct a clinical trial of SYNBIO TECH INC.'s LDL557 capsule for joint protection. To understand the improvement of joint discomfort and inflammation after supplementation, we hope to provide an updated choice for modern people's joint protection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Arthritis

Currently open trials in the same condition.

Other Chung Shan Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06658821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing